Published in Am J Respir Cell Mol Biol on November 01, 2015
Lipidome and transcriptome profiling of pneumolysin intoxication identifies networks involved in statin-conferred protection of airway epithelial cells. Sci Rep (2015) 0.76
The Use of Statins and Risk of Community-Acquired Pneumonia. Curr Infect Dis Rep (2017) 0.75
Epithelial Sodium Channel-α Mediates the Protective Effect of the TNF-Derived TIP Peptide in Pneumolysin-Induced Endothelial Barrier Dysfunction. Front Immunol (2017) 0.75
Prevalence, pathogenesis, therapy, and prevention of cardiovascular events in patients with community-acquired pneumonia. Pneumonia (Nathan) (2016) 0.75
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med (2005) 13.27
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet (2004) 6.24
Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med (2007) 5.95
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature (2002) 5.24
Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun (1989) 5.23
Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med (2008) 4.01
IL-17 markedly up-regulates beta-defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling pathways. J Immunol (2004) 3.84
Current perspectives on statins. Circulation (2000) 3.83
Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ (2006) 3.62
Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun (2006) 3.41
Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol (2001) 3.38
Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med (1995) 3.11
Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins. Proc Natl Acad Sci U S A (2004) 2.93
Repair of injured plasma membrane by rapid Ca2+-dependent endocytosis. J Cell Biol (2008) 2.66
Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev (2013) 2.49
Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun (1994) 2.49
Pore-forming protein toxins: from structure to function. Prog Biophys Mol Biol (2005) 2.36
Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe (2010) 2.28
Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation (2002) 2.20
Activation of the unfolded protein response is required for defenses against bacterial pore-forming toxin in vivo. PLoS Pathog (2008) 2.16
Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity (2007) 2.07
The airway epithelium: soldier in the fight against respiratory viruses. Clin Microbiol Rev (2011) 2.05
Role of pore-forming toxins in bacterial infectious diseases. Microbiol Mol Biol Rev (2013) 1.91
Statin effects beyond lipid lowering--are they clinically relevant? Eur Heart J (2003) 1.90
Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest (1995) 1.77
Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med (2008) 1.61
A self-regulatory system of interlinked signaling feedback loops controls mouse limb patterning. Science (2009) 1.58
Global functional analyses of cellular responses to pore-forming toxins. PLoS Pathog (2011) 1.52
Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol (2013) 1.50
Acute respiratory infections are the leading cause of death in children in developing countries. Am J Trop Med Hyg (1986) 1.46
Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest (2010) 1.44
Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol (2012) 1.44
Hypoxia and the hypoxic response pathway protect against pore-forming toxins in C. elegans. PLoS Pathog (2009) 1.35
RAB-5- and RAB-11-dependent vesicle-trafficking pathways are required for plasma membrane repair after attack by bacterial pore-forming toxin. Cell Host Microbe (2011) 1.35
Differential role of p38 mitogen activated protein kinase for cellular recovery from attack by pore-forming S. aureus alpha-toxin or streptolysin O. Biochem Biophys Res Commun (2006) 1.34
Requirements for two proximal NF-kappaB binding sites and IkappaB-zeta in IL-17A-induced human beta-defensin 2 expression by conducting airway epithelium. J Biol Chem (2008) 1.30
A conserved tryptophan in pneumolysin is a determinant of the characteristics of channels formed by pneumolysin in cells and planar lipid bilayers. Biochem J (1998) 1.30
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 1.24
Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med (2006) 1.23
Characterization of a novel long noncoding RNA, SCAL1, induced by cigarette smoke and elevated in lung cancer cell lines. Am J Respir Cell Mol Biol (2013) 1.16
HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc Res (2008) 1.09
Rho-associated protein kinase inhibition enhances airway epithelial Basal-cell proliferation and lentivirus transduction. Am J Respir Cell Mol Biol (2013) 1.07
Absorption and fluorescence spectra of polyene antibiotics in the presence of cholesterol. J Biol Chem (1992) 1.03
The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. PLoS One (2008) 1.01
Pore-forming bacterial protein toxins: an overview. Curr Top Microbiol Immunol (2001) 1.01
Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog (2014) 1.01
Innate immune responses of the airway epithelium. Mol Cells (2010) 0.99
Protein kinase C-α and arginase I mediate pneumolysin-induced pulmonary endothelial hyperpermeability. Am J Respir Cell Mol Biol (2012) 0.99
Pro-autophagic signal induction by bacterial pore-forming toxins. Med Microbiol Immunol (2010) 0.98
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia. Basic Clin Pharmacol Toxicol (2011) 0.92
Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape. PLoS One (2013) 0.89
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites. PLoS One (2011) 0.89
Variation in Streptococcus pneumoniae susceptibility to human antimicrobial peptides may mediate intraspecific competition. Proc Biol Sci (2012) 0.87
Restoration of alveolar type II cell function contributes to simvastatin-induced attenuation of lung ischemia-reperfusion injury. Int J Mol Med (2012) 0.85
Simvastatin treatment induces morphology alterations and apoptosis in murine cochlear neuronal cells. Acta Otolaryngol (2009) 0.83
Optimizing antibacterial therapy for community-acquired respiratory tract infections in children in an era of bacterial resistance. Clin Pediatr (Phila) (2004) 0.83
Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp (Warsz) (2005) 0.79
Synergistic antiproliferative and anticholesterogenic effects of linalool, 1,8-cineole, and simvastatin on human cell lines. Chem Biol Interact (2014) 0.79
Community-acquired pneumonia. Curr Opin Pulm Med (2013) 0.79
Short term statin treatment improves survival and differentially regulates macrophage-mediated responses to Staphylococcus aureus. Curr Pharm Biotechnol (2013) 0.77